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Dendritic Cell (DC) vaccination is a very promising ther-
apeutic strategy in cancer patients. The immunizing abil-
ity of DC is critically influenced by their migration activity
to lymphatic tissue, where they prime naïve T cells. In the
present study DC were differentiated from PBMC
obtained by leukapheresis (7-day culture of adherent cells
with IL-4 and GM-CSF). On day 7 the DC were defined as
immature DC (iDC). After a transient (3 h) and continu-
ous (48 h) stimulation with a cocktail of cytokines (IL-1β,
IL-6, TNF-α, PGE2), the iDC were defined as transient-
lyDC (tsDC) and mature DC (mDC), respectively. During
a phase I-II clinical vaccination trial for patients with
advanced melanoma and renal carcinoma, we evaluated
the migration ability of iDC, tsDC and mDC, and com-
pared intradermal (id) and subcutaneous (sc) administra-
tion. DC were labelled with 99Tc-HMPAO or 111In-Oxine
and the presence of labelled DC was detected in regional
lymph nodes up to a maximum of 72 h after inoculation.
It was verified that id administration resulted in about a
threefold higher migration to lymph nodes than sc admin-
istration. iDC and mDC migration was compared in 8
patients. mDC showed, on average, a six-to eightfold
higher migration than iDC. The first DC were detected in
lymph nodes after 20–60 min and the maximum concen-
tration was reached 8 h-72 h after vaccination. In two
patients a similar migration activity of mDC and tsDC was
observed up to 36 h after inoculation.
These data confirm the validity of therapeutic vaccination
with mDC administered intradermally. Further investiga-
tion is also needed to determine whether tsDC could be
used in clinical vaccination trials to have a longer T cell
activation and a more potent stimulation capacity.
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